凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
广誉远(600771)公告正文

广誉远:2014年第三季度报告

公告日期 2014-10-29
股票简称:广誉远 股票代码:600771
广誉远中药股份有限公司
GuangYuYuan Chinese Herbal Medicine Co., Ltd.
    2014 年第三季度报告
        二〇一四年十月二十九日
                                                                      广誉远中药股份有限公司 2014 年第三季度报告
                                                       目录一、 重要提示 ..........................................................................................................2二、 公司主要财务数据和股东变化 ..........................................................................2三、 重要事项 ..........................................................................................................4四、 附录 ...............................................................................................................10
                                                     广誉远中药股份有限公司 2014 年第三季度报告
    一、 重要提示
    1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、
           准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的
           法律责任。
    1.2 公司全体董事出席董事会审议季度报告。
    1.3 公司负责人董事长张斌、主管会计工作负责人傅淑红及会计机构负责人(会计主
           管人员)侯宽余保证季度报告中财务报表的真实、准确、完整。
    1.4 本公司第三季度报告未经审计。
    二、 公司主要财务数据和股东变化
    2.1 主要财务数据
                                                                     单位:元    币种:人民币
                                                                                  本报告期末比
                                本报告期末               上年度末
                                                                                上年度末增减(%)
    总资产                          602,914,649.46            526,129,197.90                     14.59
    归属于上市公司股东的净资产       49,333,986.24             47,462,751.34                      3.94
                              年初至报告期末       上年初至上年报告期末
                                                                             比上年同期增减(%)
                                (1-9 月)               (1-9 月)
    经营活动产生的现金流量净额       -9,090,913.01             23,858,802.21                   -138.10
                              年初至报告期末       上年初至上年报告期末
                                                                             比上年同期增减(%)
                                (1-9 月)               (1-9 月)
    营业收入                        260,635,433.57            187,908,906.11                     38.70
    归属于上市公司股东的净利润        1,871,234.90              1,017,493.11                     83.91归属于上市公司股东的扣除非
                                   174,950.80             -32,861,410.01                   100.53经常性损益的净利润
    加权平均净资产收益率(%)                 3.87                        2.97      增加 0.90 个百分点
    基本每股收益(元/股)                   0.008                       0.004                  100.00
    稀释每股收益(元/股)                   0.008                       0.004                  100.00
                                                                  广誉远中药股份有限公司 2014 年第三季度报告
         扣除非经常性损益项目和金额
                                                                                     单位:元      币种:人民币
                         项目                        本期金额(7-9 月)          年初至报告期末金额(1-9 月)
    非流动资产处置损益                                                                                  204,718.25
    债务重组损益                                                                                      1,592,056.72
    除上述各项之外的其他营业外收入和支出                          84,487.31                            -159,089.22
    所得税影响额                                                  14,571.17                             -22,069.40
    少数股东权益影响额(税后)                                    20,699.32                              80,667.75
                         合计                                   119,757.80                           1,696,284.10
         2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)
             持股情况表
                                                                                                       单位:股
                  股东总数(户)                                                   16,251
                                              前十名股东持股情况
    股东名称      报告期内                     比例      持有有限售条件        质押或冻结情况
                            期末持股数量                                                                股东性质
    (全称)        增减                       (%)          股份数量        股份状态          数量西安东盛集团
                                54,048,265   22.17           54,048,265     质押      54,048,265     境内非国有法人有限公司中国长城资产
                                12,200,000   5.00                            无                         国有法人管理公司鞍山钢铁集团
                 -24,000         8,064,200   3.31                            无                         国有法人公司
    郑文平           696,201         7,223,084   2.96                           未知                       境内自然人
    景旻              45,800         4,661,961   1.91                           未知                       境内自然人
    蒋仕波                           2,317,540   0.95                           未知                       境内自然人
    高雅萍                           1,576,000   0.65                           未知                       境内自然人
    蒋水良                           1,500,616   0.62                           未知                       境内自然人
    傅亚萍           174,961         1,270,151   0.52                           未知                       境内自然人上海钧齐投资
                                 1,200,000   0.49                           未知                     境内非国有法人管理有限公司
                                                                    广誉远中药股份有限公司 2014 年第三季度报告
                                            前十名无限售条件股东持股情况
                                               持有无限售条件流通股的                      股份种类及数量
                   股东名称
                                                        数量                        种类                     数量
    中国长城资产管理公司                                           12,200,000       人民币普通股                 12,200,000
    鞍山钢铁集团公司                                                8,064,200       人民币普通股                  8,064,200
    郑文平                                                          7,223,084       人民币普通股                  7,223,084
    景旻                                                            4,661,961       人民币普通股                  4,661,961
    蒋仕波                                                          2,317,540       人民币普通股                  2,317,540
    高雅萍                                                          1,576,000       人民币普通股                  1,576,000
    蒋水良                                                          1,500,616       人民币普通股                  1,500,616
    傅亚萍                                                          1,270,151       人民币普通股                  1,270,151
    上海钧齐投资管理有限公司                                        1,200,000       人民币普通股                  1,200,000
    陆红娟                                                          1,190,007       人民币普通股                  1,190,007
                                              东盛集团与其他股东之间无关联关系,其他股东之间公司未知是否存在关联上述股东关联关系或一致行动的说明
                                              关系,也未知是否属于《上市公司收购管理办法》中规定的一致行动人。
         三、 重要事项
         3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
         √适用 □不适用
                                                                                                        单位:元
                                                                                       增减变动
               科目                本期数             上年同期数
                                                                              变动金额          变动比例(%)
          营业收入            260,635,433.57         187,908,906.11         72,726,527.46                   38.70
          营业成本             58,066,648.06          82,894,251.99         -24,827,603.93                  -29.95
          销售费用            125,371,127.25          74,368,763.24         51,002,364.01                   68.58
          管理费用             52,123,410.45          57,476,174.49          -5,352,764.04                   -9.31
          财务费用              4,812,614.77            4,490,768.21           321,846.56                    7.17
          研发支出                 830,370.67           2,602,908.76         -1,772,538.09                  -68.10
          经营活动产生的
                               -9,090,913.01          23,858,802.21         -32,949,715.22              -138.10
          现金流量净额
                                                     广誉远中药股份有限公司 2014 年第三季度报告投资活动产生的
                     56,389,161.20     128,657,029.34      -72,267,868.14              -56.17现金流量净额筹资活动产生的
                    -74,340,682.46    -140,416,661.45      66,075,978.99               47.06现金流量净额
    营业税金及附加       4,232,484.94       2,344,511.84        1,887,973.10              80.53
    资产减值损失         1,570,784.07         808,012.02          762,772.05              94.40
    投资收益             -3,422,436.00                         -3,422,436.00            -100.00
    营业利润            11,035,928.03     -34,473,575.68      45,509,503.71              132.01
    营业外收入           2,202,090.86      36,108,518.94      -33,906,428.08              -93.90
    营业外支出             564,405.11       1,407,948.56         -843,543.45              -59.91
    利润总额            12,673,613.78         226,994.70      12,446,619.08             5483.22
    所得税费用           1,438,218.82         230,814.96        1,207,403.86             523.10归属于母公司
                      1,871,234.90       1,017,493.11          853,741.79              83.91所有者的净利润
    (1)营业收入较上年同期增加 7272.65 万元,增幅为 38.70%,主要是因为报告期公司精品中药及传统国药销售收入增长,公司传统中药与精品中药与上年同期相比,增幅均超过 80%,具体如下:
                                                                                   单位:万元
    品种          2014 年 1-9 月      2013 年 1-9 月        增减金额        增长比率(%)
    传统中药              16,154.61               8,525.53       7,629.08               89.49
    精品中药               5,210.63                 71.81        5,138.82             7156.13
    (2)主营业务成本较上年同期减少 2482.76 万元,减幅为 29.95%,主要是因为:公司合并报表口径的变化,本年度不再合并安徽东盛制药有限公司和东盛友邦制药有限公司两家毛利率较低的公司,同时公司产品销量大幅度增长,产品成本进一步降低;
    (3)销售费用较上年同期增加 5100.24 万元,增幅为 68.58%,主要是因为报告期公司继续加大精品中药以及传统中药实施的步伐,在各地陆续开展招商会议等精品推广活动,致力于渠道的建设和终端的全方位促销,销售费用增长幅度较大;
    (4)经营活动产生的现金流量净额较上年同期减少 3294.97 万元,减幅 138.10%,主要是因为:
    ①上年同期公司收到长城资产管理公司返还款项 4500 万元,
                                           广誉远中药股份有限公司 2014 年第三季度报告
    ②本报告期销售费用大幅度增加。
    (5)投资活动产生的现金流量净额较上年同期减少 7226.79 万元,减幅 56.17%,主要是因为上年同期公司收到房屋及土地转让余款 14600 万元,而本报告期公司该部分现金流入仅为广东恒诚制药有限公司支付的资产转让款 5750 万元;
    (6)筹资活动产生的现金流量净额较上年同期增加 6607.60 万元,增幅 47.06%,主要是因为:上年同期公司归还长城资产管理公司款项等 15511 万元,本报告期筹资活动对外支付的款项较上年度减少,主要为偿还西安东盛集团 4917 万元借款、支付给国家开发银行吉林省分行 3597 万元用以解除担保责任;
    (7)研发支出比上年度减少 177.25 万元,减幅为 68.10%,主要是因为本报告期内公司研发投入较少,而上年同期的研发支出主要为安徽东盛制药有限公司在新品研发和工艺完善方面的投入;
    (8)营业税金及附加较上年同期增加 188.80 万元,增幅为 80.53%,主要是因为本报告期公司销售收入增长幅度较大;
    (9)资产减值损失较上年同期增加 76.28 万元,增幅为 94.40%,主要是因为报告期公司针对部分专项应收款项计提了专项减值准备;
    (10)投资收益较上年同期减少 342.24 万元,减幅 100%,主要是因为报告期公司对联营企业按照权益法核算确认了当期的投资损失;
    (11)营业外收入较上年同期减少 3390.64 万元,减幅 93.90%,主要是因为本报告期债务豁免收益较上年同期较少幅度较大,仅为 159.21 万元,上年同期公司确认的河北金牛化工股份有限公司债务豁免收益为 2912.38 万元;
    (12)营业外支出较上年同期减少 84.35 万元,减幅 59.91%,主要是因为报告期内营业外支出的项目减少,上年同期主要为主要雅安地震捐助 37.99 万元、固定资产处置损失 37.57 万元以及解除合同支付的赔偿金 43.61 万元;本报告告期内主要为助学捐款等支出等。
    (13)营业利润、利润总额、所得税费用和归属于母公司所有者净利润分别较上年同期增加 4550.95 万元、1244.66 万元、120.74 万元和 85.37 万元,增幅分别为132.01%、5483.22%、523.10%和 83.91%,主要是因为报告期公司围绕“全产业链打造广誉远精品中药战略”的指导思想,积极推进“百家千店”计划,进一步挖掘广
                                            广誉远中药股份有限公司 2014 年第三季度报告誉远国药传统中药的品牌优势,销售大幅度增长,同时销售毛利率增长,使得公司收益增加,所得税费用也随之增加。
       科目              期末                 期初                变动比率(%)
    货币资金                 9,776,277.75       36,818,712.02                     -73.45
    应收票据                 3,803,471.40         7,855,345.23                    -51.58
    应收账款               148,204,815.71       90,435,139.34                      63.88
    存货                    76,505,166.92       50,985,882.42                      50.05
    长期股权投资            18,877,564.00       12,400,000.00                      52.24
    长期待摊费用             5,984,573.09           741,637.31                   706.94
    预收账款                40,847,778.47       23,728,403.04                      72.15
    应付利息                 4,944,888.97         2,467,678.97                   100.39
    预计负债                                    35,972,900.00                   -100.00
    (1)货币资金比期初减少 2704.24 万元,减幅 73.45%,主要原因为本报告期公司偿还东盛集团借款 4917 万元以及支付给国家开发银行吉林省分行 3597 万元用于解除公司对兰宝科技信息股份有限公司的担保责任;
    (2)应收票据比期初减少 405.19 万元,减幅 51.58%,主要原因为本报告期公司收到的银行承兑汇票减少;
    (3)应收账款比期初增加 5776.97 万元,增幅 63.88%,主要原因为本报告期内公司销售收入大幅增长,由于除精品中药以外,其他药品款项的收回存在一定的周期,导致应收账款随之增加;
    (4)存货比期初增加 2551.93 万元,增幅 50.05%,主要因为山西广誉远国药有限公司为消除明年 GMP 认证对市场供货的影响,加大了原材料采购及库存商品储备;
    (5)长期股权投资比期初增加 647.76 万元,增幅 52.24%,主要因为本报告期公司分别在四川、山东、河南等地投资设立精品中药销售公司;
    (6)长期待摊费用比期初增加 524.29 万元,增幅 706.94%,主要原因为本报告期北京广誉远投资管理有限公司等将新办公场所的装修工程由在建工程转入长期待摊费用核算;
                                           广誉远中药股份有限公司 2014 年第三季度报告
    (7)预收账款比期初增加 1711.94 万元,增幅 72.15%,主要原因为本报告期公司收到新设立精品国药堂及各地保健酒经销商预付的货款;
    (8)应付利息比期初增加 247.72 万元,增幅 100.39%,主要因为本报告期公司计提了东盛集团的借款利息 240.64 万元;
    (9)预计负债比期初减少 3597.29 万元,减幅 100%,主要原因为报告期内公司支付给国家开发银行吉林省分行 3597.29 万元,用以解除公司对兰宝科技信息股份有限公司的担保责任。3.2 重要事项进展情况及其影响和解决方案的分析说明√适用 □不适用
    1、2013年12月,公司与恒诚集团有限公司的子公司广东恒诚制药有限公司(以下简称“恒诚制药”)签署《资产转让合同》,根据该合同的约定,公司将分公司东盛科技股份有限公司制药一厂、东盛科技股份有限公司西安制药厂所拥有的医药资产以11,500万元的价格转让给恒诚制药。截至本报告披露日,公司已收妥恒诚制药支付的资产交易款8,050万元,并已经完成了人员交接、部分资产以及药品生产经营许可证、相关药品文号的移交过户工作,其余商标等资产的交割仍在有序推进之中;
    2、2014年7月28日,公司2014年第一次临时股东大会审议通过了公司非公开发行股票事宜,公司拟向重庆涪商投资控股集团股份有限公司、蒋仕波、陈慕群以及长安基金管理有限公司拟设立的长安天天向上龟龄集资产管理计划、长安平安富贵定坤丹资产管理计划、财富证券有限责任公司拟设立的财富证券-广誉远安宫清心集合资产管理计划非公开发行股票,发行股份总数不超过3,400万股,发行价格为18.80元/股,募集资金总额不超过63,920万元。本次非公开发行所募集资金将全部用于补充公司流动资金,以增强公司的资本实力,满足公司未来业务发展的需要。3.3 公司及持股 5%以上的股东承诺事项履行情况□适用 √不适用
                                                 广誉远中药股份有限公司 2014 年第三季度报告3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重
    大变动的警示及原因说明√适用 □不适用
    由于公司全面实施精品中药战略,加快推进“百家千店”计划,营业收入得以较快增长,以及公司预计本年度将完成与恒诚制药的资产交易,因此,年初至下一报告期期末的累计净利润与上年同期相比有较大变化,将实现扭亏为盈。3.5 执行新会计准则对合并财务报表的影响3.5.1 长期股权投资准则变动对于合并财务报告影响(一)
                                                                 单位:元     币种:人民币
                        2013 年 1 月 1                  2013 年 12 月 31 日
    被投资      交易基
                        日归属于母公司      长期股权    可供出售金融       归属于母公司
    单位      本信息
                        股东权益(+/-)   投资(+/-)   资产(+/-)      股东权益(+/-)太谷县任村信
                                           -35,321.55       35,321.55用合作社陕西广誉远龟
    龄集商贸有限                              -600,000.00      600,000.00公司
    合计                                  -635,321.55      635,321.55长期股权投资准则变动对于合并财务报告影响(一)的说明
    执行《企业会计准则第 2 号—长期股权投资》,仅对可供出售金融资产和长期股权投资两个报表项目金额产生影响,对公司 2013 年末及本期末资产总额、负债总额和净资产以及 2013 年度及本期净利润未产生影响。
                                          公司名称          广誉远中药股份有限公司
                                          法定代表人        张斌
                                          日期              2014 年 10 月 29 日
                                                  广誉远中药股份有限公司 2014 年第三季度报告四、 附录4.1 财务报表
                                  合并资产负债表
                                  2014 年 9 月 30 日
    编制单位:广誉远中药股份有限公司      单位:元      币种:人民币        审计类型:未经审计
             项目                     期末余额                       年初余额流动资产:
    货币资金                                    9,776,277.75                  36,818,712.02
    应收票据                                    3,803,471.40                   7,855,345.23
    应收账款                                 148,204,815.71                   90,435,139.34
    预付款项                                  44,159,274.38                   39,978,722.21
    其他应收款                               119,968,947.52                 109,677,101.86
    存货                                      76,505,166.92                   50,985,882.42
    流动资产合计                             402,417,953.68                 335,750,903.08非流动资产:
    可供出售金融资产                              635,321.55                     635,321.55
    长期股权投资                              18,877,564.00                   12,400,000.00
    固定资产                                 130,701,198.04                 129,021,499.84
    在建工程                                    9,839,996.77                  12,693,299.36
    固定资产清理                                                                 189,806.75
    无形资产                                  15,440,778.11                   15,679,465.79
    商誉                                      11,775,418.18                   11,775,418.18
    长期待摊费用                                5,984,573.09                     741,637.31
    递延所得税资产                              7,241,846.04                   7,241,846.04
    非流动资产合计                           200,496,695.78                 190,378,294.82
    资产总计                                 602,914,649.46                 526,129,197.90
                                                   广誉远中药股份有限公司 2014 年第三季度报告
                                合并资产负债表(续)
                                   2014 年 9 月 30 日
    编制单位:广誉远中药股份有限公司       单位:元      币种:人民币        审计类型:未经审计
             项目                       期末余额                      年初余额流动负债:
    短期借款                                   13,322,972.40                   13,322,972.40
    应付账款                                   79,688,303.46                   61,508,663.07
    预收款项                                   40,847,778.47                   23,728,403.04
    应付职工薪酬                               34,111,277.05                   28,417,959.34
    应交税费                                   49,325,899.80                   42,436,738.55
    应付利息                                     4,944,888.97                   2,467,678.97
    其他应付款                                268,602,225.06                 217,437,973.24
    流动负债合计                              490,843,345.21                 389,320,388.61非流动负债:
    预计负债                                                                   35,972,900.00
    其他非流动负债                             27,181,041.95                   27,181,041.95
    非流动负债合计                             27,181,041.95                   63,153,941.95
    负债合计                                  518,024,387.16                 452,474,330.56所有者权益(或股东权益):
    实收资本(或股本)                        243,808,438.00                 243,808,438.00
    资本公积                                  436,167,517.85                 436,167,517.85
    盈余公积                                   29,615,319.69                   29,615,319.69
    未分配利润                                -660,257,289.30               -662,128,524.20
    归属于母公司所有者权益合计                 49,333,986.24                   47,462,751.34
    少数股东权益                               35,556,276.06                   26,192,116.00
    所有者权益合计                             84,890,262.30                   73,654,867.34
    负债和所有者权益总计                      602,914,649.46                 526,129,197.90
    法定代表人:张斌             主管会计工作负责人:傅淑红            会计机构负责人:侯宽余
                                                   广誉远中药股份有限公司 2014 年第三季度报告
                                  母公司资产负债表
                                  2014 年 9 月 30 日
    编制单位:广誉远中药股份有限公司     单位:元       币种:人民币        审计类型:未经审计
             项目                      期末余额                         年初余额流动资产:
    货币资金                                      3,005,995.56                   17,746,859.73
    应收票据                                        88,753.00                       215,932.84
    应收账款                                   17,563,943.38                     17,832,066.73
    预付款项                                      1,505,490.32                    1,952,801.91
    其他应收款                                113,885,666.99                    121,402,485.33
    存货                                          7,346,596.62                    5,780,247.69一年内到期的非流动资产其他流动资产
    流动资产合计                              143,396,445.87                    164,930,394.23非流动资产:长期应收款
    长期股权投资                               85,883,535.01                     85,283,535.01投资性房地产
    固定资产                                   55,491,830.19                     57,112,517.48
    在建工程                                      9,839,996.77                    9,421,299.36
    固定资产清理                                                                    189,806.75
    无形资产                                      3,371,543.98                    3,439,238.29商誉其他非流动资产
    非流动资产合计                            154,586,905.95                    155,446,396.89
    资产总计                                  297,983,351.82                    320,376,791.12
                                                      广誉远中药股份有限公司 2014 年第三季度报告
                               母公司资产负债表(续)
                                     2014 年 9 月 30 日
    编制单位:广誉远中药股份有限公司          单位:元       币种:人民币        审计类型:未经审计
                 项目                            期末余额                    年初余额流动负债:
    短期借款                                             4,832,972.40                4,832,972.40
    应付账款                                           357,973,669.74              356,549,942.44
    预收款项                                           120,270,249.28              117,797,282.39
    应付职工薪酬                                         2,219,255.05                2,020,254.84
    应交税费                                               929,406.14                  862,648.14
    应付利息                                             4,944,888.97                2,467,678.97
    其他应付款                                         143,920,196.52              124,442,548.35其他流动负债
    流动负债合计                                       635,090,638.10              608,973,327.53非流动负债:
    预计负债                                                                        35,972,900.00
    其他非流动负债                                      10,000,000.00               10,000,000.00
    非流动负债合计                                      10,000,000.00               45,972,900.00
    负债合计                                           645,090,638.10              654,946,227.53所有者权益(或股东权益):
    实收资本(或股本)                                 243,808,438.00              243,808,438.00
    资本公积                                           396,156,422.03              396,156,422.03减:库存股
    未分配利润                                        -987,072,146.31             -974,534,296.44
    所有者权益(或股东权益)合计                      -347,107,286.28             -334,569,436.41
    负债和所有者权益(或股东权益)总计                 297,983,351.82              320,376,791.12
    法定代表人:张斌          主管会计工作负责人:傅淑红                 会计机构负责人:侯宽余
                                                         广誉远中药股份有限公司 2014 年第三季度报告
                                           合并利润表
    编制单位:广誉远中药股份有限公司          单位:元        币种:人民币       审计类型:未经审计
                                                                 年初至报告期期    上年年初至报告
                            本期金额           上期金额
           项目                                                      末金额        期期末金额(1-9
                            (7-9 月)         (7-9 月)
                                                                   (1-9 月)            月)
    一、营业总收入             98,565,030.08      57,702,955.84      260,635,433.57     187,908,906.11
    其中:营业收入             98,565,030.08      57,702,955.84      260,635,433.57     187,908,906.11
    二、营业总成本             97,144,623.72      70,219,108.21      246,177,069.54     222,382,481.79
    其中:营业成本             22,123,447.97      24,412,611.10       58,066,648.06      82,894,251.99
    营业税金及附加              1,629,961.21         729,840.71        4,232,484.94        2,344,511.84
    销售费用                   52,108,331.76      25,340,883.15      125,371,127.25      74,368,763.24
    管理费用                   19,199,110.50      18,722,467.83       52,123,410.45      57,476,174.49
    财务费用                    1,520,954.78        1,085,925.19       4,812,614.77        4,490,768.21
    资产减值损失                 562,817.50             -72,619.77     1,570,784.07          808,012.02加:公允价值变动收益(损失以“-”号填列)投资收益(损失以“-”号
                             -777,220.98                          -3,422,436.00填列)其中:对联营企业和合营
                             -777,220.98                          -3,422,436.00企业的投资收益汇兑收益(损失以“-”号填列)
                                                      广誉远中药股份有限公司 2014 年第三季度报告
                                       合并利润表(续)
    编制单位:广誉远中药股份有限公司        单位:元       币种:人民币       审计类型:未经审计
                                                              年初至报告期期    上年年初至报告
                          本期金额          上期金额
         项目                                                     末金额        期期末金额(1-9
                          (7-9 月)        (7-9 月)
                                                                (1-9 月)            月)三、营业利润(亏损以
                           643,185.38      -12,516,152.37      11,035,928.03      -34,473,575.68“-”号填列)
    加:营业外收入             184,361.25        4,957,863.58       2,202,090.86      36,108,518.94
    减:营业外支出              99,873.94         470,087.67          564,405.11        1,407,948.56其中:非流动资产处置损
                                                                    10,475.00         375,717.11失四、利润总额(亏损总额
                           727,672.69       -8,028,376.46      12,673,613.78          226,994.70以“-”号填列)
    减:所得税费用               4,133.78             22,967.65     1,438,218.82          230,814.96五、净利润(净亏损以
                           723,538.91       -8,051,344.11      11,235,394.96           -3,820.26“-”号填列)归属于母公司所有者的
                         -1,896,538.33      -7,886,902.17       1,871,234.90        1,017,493.11净利润
    少数股东损益             2,620,077.24         -164,441.94       9,364,160.06       -1,021,313.37六、每股收益:(一)基本每股收益(元/
                                -0.008                -0.03             0.008               0.004股)(二)稀释每股收益(元/
                                -0.008                -0.03             0.008               0.004股)七、其他综合收益
    八、综合收益总额           723,538.91       -8,051,344.11      11,235,394.96           -3,820.26归属于母公司所有者的
                         -1,896,538.33      -7,886,902.17       1,871,234.90        1,017,493.11综合收益总额归属于少数股东的综合
                         2,620,077.24         -164,441.94      9,364,160.06        -1,021,313.37收益总额
    法定代表人:张斌        主管会计工作负责人:傅淑红             会计机构负责人:侯宽余
                                                    广誉远中药股份有限公司 2014 年第三季度报告
                                      母公司利润表
    编制单位:广誉远中药股份有限公司        单位:元     币种:人民币      审计类型:未经审计
                                                            年初至报告期        上年年初至
                         本期金额          上期金额
           项目                                               期末金额        报告期期末金额
                         (7-9 月)        (7-9 月)
                                                              (1-9 月)        (1-9 月)
    一、营业收入             6,548,998.45     10,474,168.71     19,789,960.10       29,912,217.11
    减:营业成本             1,868,440.58      5,407,238.33      7,173,969.97       13,113,421.69
    营业税金及附加             103,874.74       110,124.75         292,312.76           326,420.23
    销售费用                 1,441,486.27      4,329,353.87      8,886,667.14       11,962,964.09
    管理费用                 4,967,162.72      5,710,476.44     14,236,728.49       16,704,518.13
    财务费用                   828,918.95       318,290.65       2,844,671.10         2,348,582.28
    资产减值损失                -50,691.17                          -56,539.97二、营业利润
                         -2,610,193.64    -5,401,315.33    -13,587,849.39       -14,543,689.31(亏损以“-”号填列)
    加:营业外收入              61,574.50      4,738,895.48      1,390,737.31       21,500,718.55
    减:营业外支出                                  6,000.00         10,475.00          383,382.55其中:非流动资产处置损
                                                                 10,475.00          373,718.42失三、利润总额(亏损总额
                         -2,548,619.14      -668,419.85    -12,207,587.08         6,573,646.69以“-”号填列)减:所得税费用四、净利润(净亏损以
                         -2,548,619.14      -668,419.85    -12,207,587.08         6,573,646.69“-”号填列)五、每股收益:(一)基本每股收益(元/股)(二)稀释每股收益(元/股)六、其他综合收益七、综合收益总额
    法定代表人:张斌            主管会计工作负责人:傅淑红              会计机构负责人:侯宽余
                                                  广誉远中药股份有限公司 2014 年第三季度报告
                                   合并现金流量表
                                   2014 年 1—9 月
    编制单位:广誉远中药股份有限公司       单位:元      币种:人民币      审计类型:未经审计
                                        年初至报告期期末            上年年初至报告期期末
                 项目
                                          金额(1-9月)                 金额(1-9月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                  242,241,933.56                216,381,602.98
    收到的税费返还                                                                  533,827.18
    收到其他与经营活动有关的现金                   23,127,132.00                 81,642,018.57
    经营活动现金流入小计                          265,369,065.56                298,557,448.73
    购买商品、接受劳务支付的现金                   79,458,174.51                106,863,224.77
    支付给职工以及为职工支付的现金                 39,745,749.97                 48,812,104.03
    支付的各项税费                                 29,356,241.28                 30,844,554.16
    支付其他与经营活动有关的现金                  125,899,812.81                 88,178,763.56
    经营活动现金流出小计                          274,459,978.57                274,698,646.52
    经营活动产生的现金流量净额                     -9,090,913.01                 23,858,802.21二、投资活动产生的现金流量:
    收回投资收到的现金                              9,070,963.34处置固定资产、无形资产和其他长期资产
                                               57,500,000.00                146,219,617.00收回的现金净额
    投资活动现金流入小计                           66,570,963.34                146,219,617.00购建固定资产、无形资产和其他长期资产
                                                3,101,802.14                  3,151,766.41支付的现金
    投资支付的现金                                  7,080,000.00
    支付其他与投资活动有关的现金                                                 14,410,821.25
    投资活动现金流出小计                           10,181,802.14                 17,562,587.66
    投资活动产生的现金流量净额                     56,389,161.20                128,657,029.34
                                                     广誉远中药股份有限公司 2014 年第三季度报告
                               合并现金流量表(续)
                                     2014 年 1—9 月
    编制单位:广誉远中药股份有限公司        单位:元       币种:人民币      审计类型:未经审计
                                          年初至报告期期末          上年年初至报告期期末
                   项目
                                            金额(1-9 月)              金额(1-9 月)三、筹资活动产生的现金流量:
    吸收投资收到的现金                                  200,000.00                  3,000,000.00
    取得借款收到的现金                                 8,490,000.00                 8,490,000.00
    收到其他与筹资活动有关的现金                    12,850,000.00                  26,908,452.42
    筹资活动现金流入小计                            21,540,000.00                  38,398,452.42
    偿还债务支付的现金                                 8,490,000.00                21,645,049.20
    分配股利、利润或偿付利息支付的现金                 2,247,782.46                 2,057,464.67
    支付其他与筹资活动有关的现金                    85,142,900.00                 155,112,600.00
    筹资活动现金流出小计                            95,880,682.46                 178,815,113.87
    筹资活动产生的现金流量净额                      -74,340,682.46               -140,416,661.45四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                    -27,042,434.27                 12,099,170.10
    加:期初现金及现金等价物余额                    36,818,712.02                   7,003,938.65
    六、期末现金及现金等价物余额                       9,776,277.75                19,103,108.75
    法定代表人:张斌          主管会计工作负责人:傅淑红               会计机构负责人:侯宽余
                                                     广誉远中药股份有限公司 2014 年第三季度报告
                                   母公司现金流量表
                                    2014 年 1—9 月
    编制单位:广誉远中药股份有限公司         单位:元     币种:人民币       审计类型:未经审计
                                            年初至报告期期末         上年年初至报告期期末
                 项目
                                              金额(1-9月)              金额(1-9月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        25,039,823.56             32,189,679.28收到的税费返还
    收到其他与经营活动有关的现金                        30,687,882.45             73,642,018.57
    经营活动现金流入小计                                55,727,706.01            105,831,697.85
    购买商品、接受劳务支付的现金                         9,190,338.33             31,406,767.75
    支付给职工以及为职工支付的现金                       8,100,109.83             12,153,637.94
    支付的各项税费                                       3,304,885.89               5,118,169.95
    支付其他与经营活动有关的现金                        42,690,665.44             48,822,109.72
    经营活动现金流出小计                                63,285,999.49             97,500,685.36
    经营活动产生的现金流量净额                          -7,558,293.48               8,331,012.49二、投资活动产生的现金流量:
    收回投资收到的现金                                   9,070,963.34取得投资收益收到的现金处置固定资产、无形资产和其他长期资产收
                                                    57,500,000.00            146,219,617.00回的现金净额收到其他与投资活动有关的现金
    投资活动现金流入小计                                66,570,963.34            146,219,617.00购建固定资产、无形资产和其他长期资产支
                                                      536,776.71                1,695,642.24付的现金
    投资支付的现金                                        600,000.00
    支付其他与投资活动有关的现金                                                  14,410,821.25
    投资活动现金流出小计                                 1,136,776.71             16,106,463.49
    投资活动产生的现金流量净额                          65,434,186.63            130,113,153.51
                                                     广誉远中药股份有限公司 2014 年第三季度报告
                                母公司现金流量表(续)
                                     2014 年 1—9 月
    编制单位:广誉远中药股份有限公司         单位:元      币种:人民币      审计类型:未经审计
                                           年初至报告期期末         上年年初至报告期期末
                   项目
                                             金额(1-9 月)             金额(1-9 月)三、筹资活动产生的现金流量:吸收投资收到的现金取得借款收到的现金
    收到其他与筹资活动有关的现金                    12,850,000.00                25,308,452.42
    筹资活动现金流入小计                            12,850,000.00                25,308,452.42
    偿还债务支付的现金                                                            7,300,000.00
    分配股利、利润或偿付利息支付的现金                   323,857.32                 374,712.00
    支付其他与筹资活动有关的现金                    85,142,900.00              155,112,600.00
    筹资活动现金流出小计                            85,466,757.32              162,787,312.00
    筹资活动产生的现金流量净额                      -72,616,757.32            -137,478,859.58四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                    -14,740,864.17                  965,306.42
    加:期初现金及现金等价物余额                    17,746,859.73                 1,812,236.40
    六、期末现金及现金等价物余额                        3,005,995.56              2,777,542.82
    法定代表人:张斌               主管会计工作负责人:傅淑红             会计机构负责人:侯宽余4.2 审计报告若季度报告经过注册会计师审计,则附录应披露审计报告正文。□适用√不适用
数据加载中...
prevnext
手机查看股票